T-cell receptor gene therapy of established tumors in a murine melanoma model

Journal of Immunotherapy

Volumn 31, Issue 1, 2008, Pages 1-6

  Abad, John D ^a   Wrzensinski, Claudia ^a   Overwijk, Willem ^b   De Witte, Moniek A ^b   Jorritsma, Annelies ^b   Hsu, Cary ^a   Gattinoni, Luca ^a   Cohen, Cyrille J ^a   Paulos, Chrystal M ^a   Palmer, Douglas C ^a   Haanen, John B A G ^b   Schumacher, Ton N M ^b   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Gene therapy; gp100 tumor antigen; Murine; T cell receptor

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 100; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC CODE; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION DOSE; T LYMPHOCYTE; TARGET CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; COCULTURE; CYTOLOGY; EXPERIMENTAL MELANOMA; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PATHOLOGY; SPLEEN; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GENE THERAPY; GENETIC VECTORS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SPLEEN; TRANSFECTION;

EID: 40749116082     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31815c193f     Document Type: Article

References (31)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
2. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
3. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
4. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512-519.
5. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457-472.
6. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287-3295.
7. Zhao Y, Zheng Z, Robbins PF, et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005;174:4415-4423.
8. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
9. + T cells. J Exp Med. 2003;198:569-580.
10. + T cell expansion and function. J Exp Med. 2005;201:139-148.
11. + T cells. J Exp Med. 2005;202:907-912.
12. + T cells. Proc Natl Acad Sci USA. 2004;101:1969-1974.
13. Onishi M, Kinoshita S, Morikawa Y, et al. Applications of retrovirus-mediated expression cloning. Exp Hematol. 1996;24:324-329.
14. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004;173:7209-7216.
15. + T cells. J Clin Invest. 2005; 115:1616-1626.
16. Jorritsma A, Gomez-Eerland R, Dokter M, et al. Selecting highly affine and well expressed TCRs for gene therapy of melanoma. Blood. 2007. [Epub ahead of print].
17. Cohen CJ, Li YF, El-Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007;67:3898-3903.
18. Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol. 2006;119:135-145.
19. Cohen CJ, Zhao Y, Zheng Z, et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006;66:8878-8886.
20. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109:2331-2338.
21. Sommermeyer D, Neudorfer J, Weinhold M, et al. Designer T cells by T cell receptor replacement. Eur J Immunol. 2006;36:3052-3059.
22. Dunn SM, Rizkallah PJ, Baston E, et al. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 2006;15:710-721.
23. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;23:349-354.
24. + T cells. Hum Gene Ther. 2004;15:648-658.
25. Wrzesinski C, Paulos CM, Gattinoni L, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. 2007;117:492-501.
26. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
27. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood. 2003;102:497-505.
28. Zhao Y, Parkhurst MR, Zheng Z, et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 2007;67:2425-2429.
29. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA. 2005;102:4518-4523.
30. Kedl RM, Rees WA, Hildeman DA, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med. 2000;192:1105-1113.
31. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.